Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy.

@article{Alqawlaq2014PreclinicalDA,
  title={Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy.},
  author={Samih Alqawlaq and Jeremy M. Sivak and John Torin Huzil and Marina Vaneva Ivanova and John G. Flanagan and Michael A. Beazely and Marianna Foldvari},
  journal={Nanomedicine : nanotechnology, biology, and medicine},
  year={2014},
  volume={10 8},
  pages={1637-47}
}
UNLABELLED Gene therapy could offer improvement in the treatment of glaucoma compared to the current standard of lowering intraocular pressure. We have developed and characterized non-viral gemini surfactant-phospholipid nanoparticles (GL-NPs) for intravitreal and topical administration. Optimized GL-NPs (size range 150-180 nm) were biocompatible with rat retinal ganglion (RGC-5) cells with >95% viability by PrestoBlue™ assay. GL-NPs carrying Cy5-labeled plasmid DNA demonstrated distinct… CONTINUE READING
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…